Inspira Technologies Raises $4.75 Million in At-the-Market Offering and Reprices Warrants

Inspira Technologies Oxy BHN ( (IINN) ) has issued an announcement.

On February 5, 2026, Inspira Technologies Oxy B.H.N. entered into a definitive agreement with a single healthcare-focused institutional investor for a $4.75 million capital raise via a registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules. The deal comprises 4 million ordinary shares and 2,785,715 pre-funded warrants at roughly $0.70 per share under a registered direct structure, alongside unregistered warrants to purchase up to 6,785,715 ordinary shares exercisable in six months at $0.70 and expiring five to five-and-a-half years after issuance. To facilitate the transaction and manage ownership limits, the company structured part of the allocation as pre-funded warrants, agreed to a 60-day lockout on new equity issuances (subject to exceptions), and retained A.G.P./Alliance Global Partners as exclusive placement agent with a 7% cash fee and expense reimbursements. Inspira also amended existing investor warrants issued in December 2023, cutting the exercise price from $1.28 to $0.70 and extending their term to February 2031, effectively repricing and lengthening a significant block of potential equity. The gross proceeds are earmarked for working capital and general corporate purposes, and the package of new securities, warrant repricing and registration commitments underscores Inspira’s ongoing effort to secure funding and strengthen its balance sheet while potentially increasing future equity dilution for shareholders.

The most recent analyst rating on (IINN) stock is a Sell with a $0.68 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.

The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies Oxy B.H.N. is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., forming the basis for the development of the next-generation INSPIRA ART500 for awake, spontaneously breathing patients. The company is also developing HYLA, a proprietary blood sensor platform for continuous, non-invasive monitoring, and positions itself as an emerging life-support and MedTech platform with multiple cleared products and a growing intellectual property portfolio.

Average Trading Volume: 164,789

Technical Sentiment Signal: Strong Sell

Current Market Cap: $24.83M

Learn more about IINN stock on TipRanks’ Stock Analysis page.